Drugs / Peginterferon α-2b
Peginterferon α-2b
also known as
PEG-IFN-α-2b · Peg-Intron · pegylated interferon alfa-2b · pegylated interferon alpha-2b
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06552429 | Aug 2024 → Oct 2025 overdue | essential thrombocythemia | Xiamen Amoytop Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT01463956 | Jan 2012 → Jun 2014 | chronic hepatitis C virus infection, cirrhosis of liver | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01657604 | Aug 2012 → May 2022 | chronic myeloid leukemia | University of Jena | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04035837 | May 2018 → Dec 2025 overdue | chronic hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07438093 | Apr 2026 → Apr 2027 expected | cancer | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| — | NCT06920329 | Apr 2025 → Dec 2027 expected | chronic hepatitis B virus infection | Xiamen Hospital of Traditional Chinese Medicine | Not yet recruiting | No outcome recorded |
| — | NCT06827249 | Mar 2025 → Jun 2026 overdue | respiratory syncytial virus bronchiolitis | Children's Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT06734637 | Nov 2024 → Nov 2026 expected | acquired polycythemia vera, essential thrombocythemia | Zhenya Hong | Recruiting | No outcome recorded |
| — | NCT07008755 | Jul 2024 → Oct 2027 expected | hand, foot and mouth disease | Zhengzhou Children's Hospital, China | Recruiting | No outcome recorded |
| — | NCT06881056 | Jul 2024 → Dec 2025 overdue | respiratory syncytial virus infectious disease | West China Second University Hospital | Recruiting | No outcome recorded |
| — | NCT06430190 | Jul 2024 → Jan 2025 | anogenital human papillomavirus infection | Zhangyu Bu | Unknown | No outcome recorded |
| — | NCT06323681 | Feb 2024 → Feb 2027 expected | chronic hepatitis B virus infection | Qing XIe | Recruiting | No outcome recorded |
| — | NCT06707922 | Mar 2022 → May 2029 expected | chronic hepatitis B virus infection | Xiamen Amoytop Biotech Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01949168 Comparator | Sep 2013 → Sep 2015 | chronic hepatitis C virus infection | St Vincent's Hospital Melbourne | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-10-01 | Merck Sharp & Dohme LLC | Results Merck to Present New Data for VICTRELIS® (boceprevir) and MK-5172 at The American Association for the Study of Liver Diseases 2012 Annual Meeting merck.com ↗
Timing and Magnitude of Ribavirin Dose Reduction (RBV DR) Do Not Impact Sustained Virologic Response Rates with Boceprevir (BOC) + Peginterferon alfa-2b / Ribavirin (P/RBV) in the Anemia Management Study in Chronic HCV Genotype 1 Patients. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-10-01 | Merck Sharp & Dohme LLC | Merck to Present New Data for VICTRELIS® (boceprevir) and MK-5172 at The American Association for the Study of Liver Diseases 2012 Annual Meeting merck.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon α2b | “Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-Suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China.” PMID 41638418 ↗ Feb 202614“Peginterferon α2b Injection in the Treatment of Pediatric RSV Bronchiolitis” NCT06827249 ↗ |
| Known as | PEG-IFN-α-2b | “Patients with NA-suppressed CHB who were hepatitis B e antigen (HBeAg)-negative, had HBsAg ≤1500 IU/mL, and undetectable HBV DNA, were administered PegIFNα-2b for 48 weeks,...” PMID 41638418 ↗ Feb 20262“All patients received PEG-IFN-α-2b-based therapy, achieved HBV DNA negativity and HBsAg clearance, and were followed-up for at least 48 weeks after discontinuation of medications.” PMID 40390028 ↗ May 2025 “pegylated interferon alpha-2b (Peg-IFNα2b) combined with PD-1 monoclonal antibody.” NCT07438093 ↗ |
| Known as | Peg-Intron | “Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection” NCT01949168 ↗ |
| Known as | pegylated interferon alfa-2b | “Pegylated interferon alfa-2b (Peg-IFN α-2b), a first-line treatment for hepatitis B virus (HBV) infection, can significantly achieve HBsAg clearance in clinic.” PMID 36944116 ↗ Mar 2023 |
| Known as | pegylated interferon alpha-2b | “pegylated interferon alpha-2b (Peg-IFNα2b) combined with PD-1 monoclonal antibody.” NCT07438093 ↗ |
| Modality | Protein / enzyme biologic | “pegylated interferon alpha-2b (Peg-IFNα2b)” NCT07438093 ↗ |
| Route | Subcutaneous | “Peg-Interferon α-2b by subcutaneous injection” NCT01463956 ↗ |